Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window

 With reference to the above subject, this is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with NSE Circular Reference no. NSE/CML/2019/11 and BSE Circular Reference no. LIST/COMP/01/2019-20, both dated April 02, 2019 Trading Window for dealing in Securities of the Company will remain closed for all Directors, Officers, Designated Persons of the Company and their immediate relatives with effect from Friday, January 01, 2021 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended December 31, 2020. The date of meeting of Board of Directors to approve the Financial Results of the Company for the quarter ended December 31, 2020 will be informed in due course. You are requested to kindly note the same.
31-12-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015

 As informed earlier, KILITCH has already set up its second green field project in Ethiopia under name of Kilitch Estro Biotech PLC, Ethiopia, a foreign subsidiary of the Company, at Oromia Special Zone, Ethiopia, on invitation of Ethiopian Government. We are delighted to share that aforesaid subsidiary Company has received the Manufacturing License to produce 'Cephalosporin' Dry Powder Injections / Tablets / Capsules & Dry syrup at Kilitch Estro Biotech PLC, Addis Ababa, Ethiopia w.e.f. December 18, 2020. We have setup the state of art dedicated Cephalosporin facility and production of the same will commence soon. This facility will help us to address the immense prospects in Ethiopian local market and African continent. Grant of manufacturing license is a stepping stone for Kilitch foray in Africa & this expansion would ensure volume growth and better profitability in coming years ahead. The above is for information and dissemination to the public at large.
18-12-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Of Related Party Transaction Pursuant To Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 23(9) of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transaction on consolidated basis for the half year ended 30th September, 2020, in the format specified on the relevant accounting standards. Kindly take the same into your records.
03-12-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Outcome Of Board Meeting Held On November 13, 2020

 We wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. November 13, 2020, have Considered & approved the Un-audited financial results of the company for the quarter and half year ended September 30, 2020. In this connection please find enclosed the copy of Un-audited standalone & consolidated financial Results of the Company for the quarter and half year ended September 30, 2020 along with Limited Review Report by the Statutory Auditors of the Company as 'Annexure-I'. The meeting commenced at 12:30 P.M. (IST) and concluded at 4:45 P.M.(IST) The above is for information and dissemination to the public at large.
13-11-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Quarterly Results

 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2020 ,inter alia, to consider and approve To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter/half year ended September 30, 2020; Any other matter with the permission of the Chair.
06-11-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 27, 2020 for Bhavin Mehta
28-10-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 26, 2020 for Bhavin Mehta
26-10-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 22, 2020 for Bhavin Mehta
23-10-2020
Bigul

Kilitch Drugs India Ltd - 524500 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For Half Year Ended September 30, 2020

 Please find enclosed Compliance Certificate pursuant to the Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2020.
20-10-2020
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on Ocotber 19, 2020 for Bhavin Mehta
19-10-2020
Next Page
Close

Let's Open Free Demat Account